Investigating a new approach to reduce lung fibrosis
Fibronectin Extra Domain A Degradation as an Antifibrotic Approach in Lung Fibrosis
This study is looking at a protein called FN-EDA to see how it affects lung fibrosis, a condition that makes it hard to breathe, and aims to find new ways to help people with this condition feel better.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11056059 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein variant, Fibronectin Extra Domain A (FN-EDA), contributes to lung fibrosis, a serious condition that thickens lung tissue and impairs breathing. The study aims to explore the mechanisms of protein degradation that could potentially reduce fibrosis. By targeting FN-EDA, the researchers hope to develop new therapeutic strategies to alleviate the symptoms and progression of chronic lung diseases. Patients with pulmonary fibrosis may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis or related interstitial lung diseases.
Not a fit: Patients with acute lung injuries or those without any form of lung fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life and survival rates for patients with lung fibrosis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating fibrotic diseases, indicating that this approach could be a viable option.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Evankovich, John W — University of Pittsburgh at Pittsburgh
- Study coordinator: Evankovich, John W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.